Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2525163 | 0.84 | MAPK8 (0.56) | MAPK8BTKHTR7NPC1ALDH1A1 | |
| SCHEMBL7565905 | 0.82 | NCF1 (0.42) | MAPK8HTR7 | |
| SCHEMBL8504109 | 0.80 | MCHR1 (0.43) | HTR7 | |
| SCHEMBL7161 | 0.79 | HTR7 (0.61) | MAPK8BTKHTR7NPC1ALDH1A1 | |
| SCHEMBL27564139 | 0.79 | DRD4 (0.36) | HTR7MAPTDRD4 | |
| SCHEMBL23462621 | 0.79 | DRD4 (0.36) | HTR7MAPTDRD4 | |
| SCHEMBL113568 | 0.79 | HTR7 (0.44) | HTR7MAPTDRD4 | |
| SCHEMBL2370822 | 0.79 | NUDT1 (0.50) | HTR7MAPTDRD4 | |
| SCHEMBL16511922 | 0.78 | BTK (0.65) | MAPK8BTKHTR7NPC1ALDH1A1 | |
| SCHEMBL7564408 | 0.78 | HTR7 (0.41) | HTR7FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | MAPK8 568/4885BTK 871/4885HTR7 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.